Docosahexaenoic acid - Martek Biosciences

Drug Profile

Docosahexaenoic acid - Martek Biosciences

Alternative Names: ARASCO; DHA - Martek Biosciences; DHA GOLD; DHASCO; Formulaid; Life'sDHA; Neuromins

Latest Information Update: 23 Apr 2015

Price : $50

At a glance

  • Originator Martek Biosciences
  • Developer Martek Biosciences; National Institutes of Health (USA)
  • Class Antihyperlipidaemics; Docosahexaenoic acids; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Nutrition disorders
  • No development reported Alzheimer's disease
  • Discontinued Breast cancer; Colorectal cancer; Hyperlipidaemia; Malignant melanoma

Most Recent Events

  • 23 Apr 2015 No recent reports of development identified - Phase-III for Alzheimer's disease in USA (PO)
  • 22 Feb 2011 DSM acquires Martek Biosciences
  • 02 May 2007 Preclinical data added to the Alzheimer's Disease and Cognition Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top